{
    "clinical_study": {
        "@rank": "13422", 
        "arm_group": [
            {
                "arm_group_label": "Levothyroxin", 
                "arm_group_type": "Experimental", 
                "description": "In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothyroidism is risk factor in atherosclerotic cardiovascular diseases, but there is a\n      controversy in effect of subclinical hypothyroidism on cardiovascular diseases. We aim to\n      estimate the relation between subclinical hypothyroidism and endothelial dysfunction and the\n      effects of levothyroxine therapy on it. Patients with confirmed subclinical hypothyroidism\n      by lab results will be randomized to two groups of treatment with one daily dose of 100 mg\n      Levothyroxine or placebo. The flow-mediated dilation and intima media thickness are\n      evaluated before and after the study."
        }, 
        "brief_title": "Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Subclinical Hypothyroidism", 
        "condition_browse": {
            "mesh_term": "Hypothyroidism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18 to 65\n\n          -  confirmed subclinical hypothyroidism\n\n        Exclusion Criteria:\n\n          -  receiving of other treatments for hypothyroidism\n\n          -  patients with other major medical disorders\n\n          -  smoking\n\n          -  hyperlipidemia\n\n          -  obesity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090907", 
            "org_study_id": "392349"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levothyroxin", 
                "intervention_name": "Levothyroxine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Subclinical hypothyroidism", 
            "Atherosclerosis", 
            "Cardiovascular disease", 
            "Endothelial function", 
            "Prevention"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Khorshid endocrinology clinic"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism", 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Nasmi Niknam, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Flow-mediated dilation will be assessed using standard method with a radiologist unaware to the study arms at baseline and then 2 months after treatment.", 
                "measure": "Change from baseline flow-mediated dilation at 2 months", 
                "safety_issue": "No", 
                "time_frame": "At baseline and then 2 months after treatment"
            }, 
            {
                "description": "Intima-media thickness will be assessed using standard method with a radiologist unaware to the study arms at baseline and then 2 months after treatment.", 
                "measure": "Change from baseline intima-media thickness at 2 months", 
                "safety_issue": "No", 
                "time_frame": "At baseline and then 2 months after treatment"
            }
        ], 
        "reference": [
            {
                "PMID": "16314542", 
                "citation": "Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005 Nov 28;165(21):2467-72."
            }, 
            {
                "PMID": "21505892", 
                "citation": "Alibaz Oner F, Yurdakul S, Oner E, Kubat Uzum A, Erguney M. Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism. Endocrine. 2011 Oct;40(2):280-4. doi: 10.1007/s12020-011-9465-2. Epub 2011 Apr 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090907"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Nasmi Niknam", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}